The expression of formyl peptide receptor 2 (FPR2) was significantly lower in focal cortical dysplasia type IIb (FCDIIb) and tuberous sclerosis complex (TSC) cortical lesions than in controls, and the protein level of FPR2 was negatively correlated with seizure frequency in FCDIIb and TSC patients, which indicate that FPR2 activation may be a potential strategy for attenuating seizures and for uniform progression of epilepsy in FCDIIb and TSC patients. The gene discussed is FPR2; the disease is tuberous sclerosis.